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dbstract
ackground: The effect of corticosteroid treatment on the viral load of Severe Acute Respiratory Syndrome (SARS) patients is unknown.
bjective: To compare the plasma SARS-CoV RNA concentrations in ribavirin-treated patients who received early hydrocortisone therapy
ith those who received placebo.
tudy design: Serial plasma SARS-CoV RNA concentrations measured in the setting of a prospective, randomized double-blinded, placebo-
ontrolled trial designed to assess the efficacy of “early” (<7 days of illness) hydrocortisone use in previously healthy SARS patients were
nalyzed. SARS-CoV RNA was quantified using a one-step real-time RT-PCR assay targeting the nucleocapsid gene.
esults: Among 16 non-ICU cases, SARS-CoV RNA was detected in plasma since day 3–4 after fever onset; viral concentration peaked in
he first week, which then rapidly declined in the second week of illness. On days 8, 12, 16, and 20, the cumulative proportion of patients with
ndetectable virus in plasma was 31%, 69%, 92%, and 100%, respectively. Plasma SARS-CoV RNA concentrations in the second and third
eek of illness were significantly higher in patients who received initial hydrocortisone treatment (n = 9), as compared to those who received
lacebo (n = 7)(AUC; Mann–Whitney, P = 0.023). The median time for SARS-CoV to become undetectable in plasma was 12 days (11–20
ays) versus 8 days (8–15 days), respectively.
onclusion: Our findings suggested “early” corticosteroid treatment was associated with a higher subsequent plasma viral load.
2004 The Chinese University of Hong Kong. Published by Elsevier B.V. All rights reserved.
eywords: SARS; Plasma viral load; Corticosteroid
. Introduction
Severe Acute Respiratory Syndrome (SARS) is a newly
merged infectious disease; little is known about its patho-
enesis and its optimal treatment regimen (Peiris et al.,
003a). The use of corticosteroid therapy to reduce possible
∗ Corresponding author. Tel.: +852 2632 2563; fax: +852 2194 6171.
E-mail address: loym@cuhk.edu.hk (Y.M.D. Lo).
immune-mediated pulmonary damage remains controversial
(Oba, 2003). We previously described a real-time quantitative
reverse transcriptase polymerase chain reaction (RT-PCR)
plasma/serum assay for early diagnosis of SARS (Ng et al.,
2003). In this study, we analyzed serial plasma SARS-CoV
RNA concentrations measured in the setting of a randomized,
placebo-controlled trial initially designed to assess the effi-
cacy of “early” hydrocortisone use (initiated <7 days from
fever onset) in previously healthy SARS patients. Effect of
386-6532/$ – see front matter © 2004 The Chinese University of Hong Kong. Published by Elsevier B.V. All rights reserved.
oi:10.1016/j.jcv.2004.07.006
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corticosteroid treatment on plasma viral load was studied by
comparing hydrocortisone-treated patients versus those who
received placebo.
2. Methods
A prospective, randomized, double-blinded, placebo-
controlled trial to assess for the clinical efficacy of early
corticosteroid use on SARS patients was conducted during
20th April 2003 to 30th May 2003 in two regional hospitals
in Hong Kong. Ethics approval was obtained from the In-
stituional Review Board of the Chinese University of Hong
Kong. However, the study was terminated because the Hong
Kong outbreak ended in June 2003. The study inclusion cri-
teria were: (1) “Probable” cases of SARS with or without
laboratory confirmation according to the Center for Disease
Control and Prevention (CDC) case definition (CDC, 2003)
and (2) age 18–65 years. Exclusion criteria were: (1) late
presentation on ≥5 days after symptom onset; (2) presence
of co-morbidity (e.g. renal impairment, liver failure, conges-
tive heart failure, major cardiovascular diseases, chronic lung
diseases, malignancy, etc.); and (3) evidence of respiratory
failure on admission as defined by blood oxygen saturation
(SaO2 )≤ 90% or oxygen tension of PaO2 < 8 kPa without sup-
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avirin therapy at a dose of 400 mg eight hourly was given
if there was no clinical response after 48 h, for a total of 12
days. Also, cases were randomised in a double-blind fash-
ion to receive either (1) “early” intravenous hydrocortisone
100 mg every eight hourly, or (2) intravenous normal saline
5 mL eight hourly as placebo, for a total of 12 days, or
until “pulse” methylprednisolone was given as rescue ther-
apy. “Pulse” of intravenous high-dose methylprednisolone
(500 mg/day for three consecutive days) was given for cases
having persistent/recurrent fever plus radiographic progres-
sion of lung opacities± hypoxemia as rescue therapy. Further
pulses of methylprednisolone were given as required when
no clinical or radiological improvement archived, up to a
total of 3.0 g (Sung et al., 2004). Detailed clinical, radio-
logical, and laboratory data in patients treated similarly had
been described elsewhere (Sung et al., 2004; Hui et al., in
press).
2.1. Statistical analysis
Data was analyzed using summary statistics and the area
under curve (AUC) method. Mann–Whitney test was used to
compare plasma viral concentrations between different arms
across time, which were quantified by mean AUC, as calcu-
lated by the linear trapezoidal method. Spearman’s rank cor-
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tlemental oxygen therapy (i.e. in room air). Informed con-
ents from patients were obtained. Routine serial laboratory
nvestigations and plain chest radiographs were performed
s described (Lee et al., 2003; Sung et al., 2004). Extent of
ulmonary infiltrates on each frontal chest radiograph was
cored in percentages by radiologists (Wong et al., 2003).
onventional, qualitative SARS-CoV RT-PCR assays were
erformed weekly on throat gargles and stool specimens for
ach patient; and paired SARS-CoV serology (indirect im-
unofluorescence assay, 2–4 weeks apart) were also obatined
WHO, 2003; Chan et al., 2004). Plasma SARS-CoV RNA
oncentrations were measured daily from the day of admis-
ion until discharge.
For plasma SARS-CoV RNA quantitation, blood samples
ere collected in EDTA-containing tubes. Plasma was ob-
ained by centrifuging the blood samples at 1600 × g for
0 min, followed by 16,000 × g for 10 min. Viral RNA was
xtracted from 0.28 mL plasma by a QIAamp viral RNA
ini kit (Qiagen, Hilden, Germany) according to the man-
facturer’s recommendations. RNA was eluted with 50L
f AVE buffer (included in the kit) and stored at −80 ◦C.
ne step quantitative real-time RT-PCR targeting the nucle-
capsid gene of the SARS-CoV was performed as previously
escribed to determine the plasma viral RNA concentrations
Ng et al., 2003). Each sample was analyzed in duplicates,
nd the calibration curve was run in parallel for each analysis.
ultiple negative water blanks were also included in every
nalysis.
The clinical treatment protocol consisted of initial antibac-
erial therapy for community-acquired pneumonia (Lee et al.,
003; Sung et al., 2004) upon admission. Intravenous rib-elation coefficient was used to assess for correlation between
lasma viral concentrations and the extent of lung opacities
n plain chest radiographs or the nadir lymphocyte counts.
PSS for Windows (Release 11.5; SPSS Inc., Chicago, IL,
SA) was used for the analyses, and the level of significance
as set at 0.05 for all comparisons.
. Results
A total of 17 patients were recruited. Their median age
as 34 years (range 22–57 years), with a male to female ra-
io of 1:3. All were previously healthy individuals. Paired
erology testing confirmed SARS-CoV infection in 16 cases
IgG titer 40–640); five had bilateral lung infiltrates, with
ne case requiring supplemental oxygen therapy. All recov-
red and discharged uneventfully without requiring ICU care.
he remaining patient was transferred to ICU and mechani-
al ventilated because of respiratory failure and died before
convalescence serum could be obtained. His diagnosis of
ARS was confirmed by two throat washings tested positive
or SARS-CoV by RT-PCR.
The clinical, radiological, and laboratory data in our co-
ort is summarized in Table 1. A total of nine patients in the
on-ICU group received “early” hydrocortisone treatment,
nitiated at a mean interval of 4.8 days (95% CI: 4.1–5.5)
rom fever onset. Normal saline was given in the remain-
ng seven cases. High-dose methylprednisolone was given
o six (86%) patients in the placebo group (mean cumula-
ive dose = 1.8 g) and four (44%) patients in the hydrocor-
isone group (mean cumulative dose = 2.2 g), respectively,
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Table 1
Clinical, radiological, and laboratory data in the “early hydrocortisone” treated group vs. “placebo” group
Early hydrocortisone Placebo
Number of cases 9 7
Mean age (years) 35 34
Male:female 1:3.5 1:2.5
Cases given methylprednisolone (number) 4 6
Total methylprednisolone dosage (g) 2.2 1.8
Initial extent of pulmonary infiltrate (%) [95% CI] 1.48 [0.43–2.53] 1.67 [0.26–3.07]
Peak extent of pulmonary infiltrate (%) [95% CI] 4.54 [2.06–7.02] 5.00 [2.19–7.81]
Initial lymphocyte count (109 L−1) [95% CI] 0.83 [0.56–1.10] 0.7 [0.56–0.84]
Nadir lymphocyte count (109 L−1) [95% CI] 0.49 [0.32–0.66] 0.36 [0.20–0.52]
Initial LDH level (IU/L) [95% CI] 208.33 [181.89–234.77] 193.43 [125.27–261.59]
Peak LDH level (IU/L) [95% CI] 346.44 [241.23–451.66] 346.14 [170.10–522.19]
Peak CRP level (mg/L) [95% CI] 34.89 [11.99–57.79] 35.33 [10.01–69.65]
Cases with positive RT-PCR result on respiratory/stool specimens (%) 5 (55.6) 3 (42.9)
Cases with positive RT-PCR result on respiratory specimens (%) 4 (44.4) 2 (28.6)
LDH, lactate dehydrogenase; CRP, C-reactive protein; RT-PCR, reverse transcriptase polymerase chain reaction.
initiated at a mean interval of 8.6 days from illness onset.
The single ICU case received both “early” hydrocortisone
treatment and subsequent high-dose methylprednisolone
therapy.
The detectability (percentage of patients) of plasma
SARS-CoV RNA in 16 non-ICU patients (hydrocortisone-
treated group versus placebo group) across time is depicted
in Fig. 1. SARS-CoV RNA was detected in plasma since day
3–4 after illness onset. Overall, the mean time for SARS-
CoV RNA to become undetectable in plasma was 11.9 days
(95% CI: 9.7–14.1) from fever onset; cumulative proportion
of patients with undetectable virus was 31%, 69%, 92%,
and 100%, on days 8, 12, 16, and 20, respectively. Median
F ring the
g
time for SARS-CoV RNA to become undetectable in plasma
was 12 days (range 11–20 days) versus 8 days (range 8–15
days) in the hydrocortisone and placebo groups, respectively
(Mann–Whitney; P = 0.106).
Profile of mean plasma SARS-CoV RNA concentrations
in 16 non-ICU cases (hydrocortisone-treated group versus
placebo group) is depicted in Fig. 2. In general, peak plasma
viral load was reached within the first week of illness and
rapidly declined in the second week. The mean peak plasma
SARS-CoV RNA concentration was 510 copies/mL (95%
CI: 148–1738 copies/mL). The peak value in the single ICU
case was 35,086 copies/mL. The plasma viral loads mea-
sured in the two treatment arms were compared. Plasmaig. 1. Percentage of patients with detectable plasma SARS-CoV RNA du
roup; ( ) “placebo” group.ir first 3 weeks of illness. ( ) “Early hydrocortisone” treated
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Fig. 2. Profile of mean plasma SARS-CoV RNA concentrations in the “early hydrocortisone” treated group vs. “placebo” group. ( ) “Early
hydrocortisone” treated group (mean, S.E.); ( ) “placebo” group (mean, S.E.).
SARS-CoV RNA concentrations in the second and third
week of illness were statistical significantly higher in pa-
tients who received early hydrocortisone treatment (n = 9),
as compared to those who received placebo (n = 7) (AUC;
Mann–Whitney, P = 0.023). No difference in plasma viral
RNA concentrations was detected between those who ever
received subsequent high dose methylprednisolone (n = 10)
and those who did not (n = 6) (AUC; Mann–Whitney, P
> 0.05).
In addition, patients who had upper respiratory speci-
men(s) tested positive for SARS-CoV by RT-PCR (n = 6)
had statistical significantly higher plasma viral RNA concen-
trations comparing to cases tested negative (n = 11) (AUC;
Mann–Whitney test, P = 0.037). No difference in plasma
viral RNA concentrations was detected between fecal spec-
imen positive (n = 4) and negative (n = 13) patients (AUC;
Mann–Whitney test, P > 0.05). Furthermore, no statistically
significant difference in plasma viral RNA concentrations
was detected between patients who ever had bilateral lung
infiltrates (n = 6) and those who had not (n = 11) (AUC;
Mann–Whitney, P > 0.05). No significant correlation was
found between plasma SARS-CoV RNA concentration and
the extent of lung opacities (%) on plain chest radiographs
(Spearman’s r = +0.321), or their respective peak values
(Spearman’s r = +0.144). Also, no significant correlation
b
t
f
4. Discussion
In young, previously healthy adult SARS patients, SARS-
CoV RNA was detected in plasma since day 3–4 after fever
onset, reaching its peak concentration in the first week, and
declined rapidly in the second week of illness. “Early” hy-
drocortisone treatment initiated in <7 days of illness was as-
sociated with significantly higher subsequent plasma viral
concentrations in the second and third week. Duration of vi-
raemia may also be prolonged.
Our findings confirmed previous observations that “viral
load” of SARS patients declined rapidly in the second week
of illness after an initial peak (day 10 in upper respiratory
secretions) (Peiris et al., 2003b; Ng et al., 2003). Since rib-
avirin has no demonstrable antiviral activity against SARS-
CoV (Cyranoski, 2003), host immune defense is likely to be
responsible for viral clearance. As shown in our study, “early”
initiation of corticosteroid treatment during the viral replica-
tion phase (Peiris et al., 2003b; Wong and Hui, 2003) in the
first week of illness resulted in delayed viral clearance (thus a
higher subsequent plasma viral load), which possibly related
to its immunosuppressive effect. Duration of viraemia might
also be prolonged (median time to undetectable = 12 days
versus 8 days), though the difference did not reach statistical
significance.
t
ietween peak plasma SARS-CoV RNA concentrations and
he nadir lymphocyte counts (Spearman’s r = +0.082) was
ound.The use of corticosteroid therapy in SARS patients is con-
roversial (Oba, 2003). Its immunosuppressive effect (SARS
s a viral induced pneumonia), potential side effects (e.g.
308 N. Lee et al. / Journal of Clinical Virology 31 (2004) 304–309
superimposed bacterial/fungal infections, hyperglycemia,
electrolyte imbalance, psychosis), and lack of evidence on
clinical efficacy from randomized/placebo-controlled stud-
ies were the main concerns (Wang et al., 2003; Peiris et al.,
2003a). Corticosteroid was given to reduce possible immuno-
pathological damage. Preliminary data from retrospective,
non-randomized studies did demonstrate some clinical bene-
fits in SARS patients receiving corticosteroid treatment (Sung
et al., 2004; Ho et al., 2003). However, the optimal timing and
dosage of such therapy is uncertain. Results from our anal-
ysis do not support the use of corticosteroid therapy early
in the illness because of delayed viral clearance, especially
when no concomitant effective antiviral therapy is given. In
fact, as shown in a separate study, “early” low-dose corti-
costeroid/hydrocortisone therapy failed to halt disease pro-
gression in >80% of cases (Sung et al., 2004). Although we
did not observe abrupt rebound of viraemia in our cohort af-
ter “pulse” methylprednisolone therapy given after the first
week, further study is needed to clarify the issue. Meanwhile
we call for cautious use of such therapy; and if used, prefer-
ably given in later course of the disease, when an overexuber-
ant host immune response is causing pathological lung dam-
age (e.g. in the second week following clinical deterioration)
(Peiris et al., 2003b; Loutfy et al., 2003; Wong and Hui, 2003),
and when SARS-CoV viral load had declined significantly.
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load and therefore should be avoided. Judicious use of corti-
costeroid therapy in SARS is advisable.
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